Bio-Rad Laboratories (BIO) Earnings Date & Reports

Bio-Rad reported First-Quarter 2026 net sales of $592.1 million, surpassing some analyst expectations near $587 million but reflecting modest 1.1% reported growth from $585.4 million in Q1 2025. On a currency-neutral basis, sales fell 4.2% year-over-year.+Tops+Q1+EPS+by+5c,+Beats+on+Revenue;+Offers+Guidance/26408481.html) The Life Science segment delivered $228.5 million, flat reported but down 4.3% currency-neutral, pressured by weak academic end-markets. Clinical Diagnostics generated $363.6 million, up 1.9% reported yet down 4.1% currency-neutral due to Middle East conflicts.

GAAP gross margin held steady at 52.3%, while non-GAAP was 53.1%, down from 53.8% last year. GAAP operating income rose to $34.1 million from $23.7 million, but non-GAAP fell to $39.3 million. Non-GAAP diluted EPS of $1.89 trailed consensus estimates, reflecting higher operating expenses and currency impacts. A significant GAAP net loss stemmed from the Sartorius investment valuation change. Positively, net cash from operations was $108.1 million, yielding $78.1 million in free cash flow.

AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore the AI Screener to enhance your analysis.

Market Reaction and Investor Sentiment

Following the April 30 release, Bio-Rad's stock climbed about 1.8% to $275.15 in after-hours trading, suggesting investors valued the cash flow strength and operational resilience over the EPS miss and guidance cut. Sentiment remains cautious, with focus on currency headwinds and segment-specific pressures, though share repurchases signal management confidence.

Forward Outlook and Key Factors to Monitor

Bio-Rad updated its full-year 2026 guidance, narrowing currency-neutral revenue growth to -3.0% to +0.5% from prior +0.5% to +1.5%, and non-GAAP operating margin to 10.0%-12.0% from 12.0%-12.5%. This reflects persistent academic market softness and regional diagnostics disruptions.

Investors should track recovery in Life Science academic demand, especially in the Americas, and stabilization in Clinical Diagnostics amid Middle East tensions. Cost optimization efforts, including organizational streamlining, could support margins. Strong cash generation positions the company for continued share repurchases and potential strategic investments.

Upcoming catalysts include Q2 results, further updates on Sartorius investment volatility, and broader biotech funding trends. Currency fluctuations remain a risk, but durable free cash flow provides a buffer. Monitoring these dynamics will clarify the path to guidance achievement and segment rebound.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations